You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Commercialization of a Novel Therapeutic for Alzheimer's Disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    ABSTRACT Dental implants are a central part of modern dental practice with the overall market for replacement and reconstruction of teeth expected to reach over $billion in the next several yearsIt is estimated that overmillion people in the United States are missing all of the teeth in one or both of their jaws leading to lower quality of lifeMost of these implants will be successful for long ter ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Augmenting Dual Energy CT for Novel Contrast Agents

    SBC: NEXTRAST, INC            Topic: 300

    Project SummaryAbstract Our long term goal is to revolutionize the effectiveness of CT imaging for millions of Americans across a broad range of abdominal diseaseDual energy CTDECTprovides powerful clinical diagnostic potential but remains heavily underutilized despite wide scanner availabilityDECT allows materials to be differentiated based on their relative X ray attenuation at low versus high e ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine

    SBC: 490 BIOTECH INC            Topic: 400

    Expressing humanized bacterial luciferase in stem cellsMoving beyond firefly luciferase toexpand the informational capacity of animal models for regenerative medicine Project Summary This Small Business Technology TransferSTTRPhase II project proposes to develop complementary autonomously bioluminescentautobioluminescentin vitro stem cell lines and in vivo small animal model systems that enable th ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Assessment to Accelerate Diagnostic Skill Acquisition, Phase II

    SBC: Parallel Consulting, LLC            Topic: 300

    Project Summary Today s clinical learning environments do not provide the level of deliberate practicedirect supervisionand rigorous assessment and feedback needed to develop diagnostic reasoning expertiseClinical performance assessment emphasizes learner evaluation over learner developmentlacks rigor and utility for developmental purposesand clinical teachers have expressed particular difficulty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Portable System with Li Foil MWPC Neutron Detectors

    SBC: Radiation Detection Technologies, Inc.            Topic: DTRA14B005

    At the completion of the research and development effort a Li-foil multi-wire proportional counter (MWPC) neutron detector with more than 625-cm2 of active area will be included in a portable radiation detection system. The system is expected to outperform the standards set by the ANSI N42.53 standards, and gamma-ray rejection ratio (GRR) of 1.0x10-8 or better. A gamma-ray spectrometer for isotope ...

    STTR Phase II 2017 Department of DefenseDefense Threat Reduction Agency
  10. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government